Dicerna Pharmaceuticals presented updated data from its ongoing PHYOX1 Phase 1 clinical trial evaluating DCR-PHXC, the Company’s lead GalXC product candidate. The data was presented in a poster at the German Society of Pediatric Nephrology 50th Annual Meeting in...